Financial Results - Standalone (Q2 FY27)

  • Revenue from operations: ₹6,470.82 million (Q2 FY27) vs ₹5,266.69 million (Q2 FY26) - 22.9% increase
  • Other income: ₹38.36 million (Q2 FY27) vs ₹149.33 million (Q2 FY26)
  • Total income: ₹6,509.18 million (Q2 FY27) vs ₹5,416.02 million (Q2 FY26)
  • Profit before tax: ₹1,283.08 million (Q2 FY27) vs ₹1,108.71 million (Q2 FY26)
  • Tax expense: ₹322.95 million (₹263.67 million current tax + ₹59.28 million deferred tax)
  • Net profit: ₹960.13 million (Q2 FY27) vs ₹829.49 million (Q2 FY26) - 15.8% increase
  • EPS (Basic): ₹4.52 (Q2 FY27) vs ₹3.97 (Q2 FY26)
  • EPS (Diluted): ₹4.48 (Q2 FY27) vs ₹3.89 (Q2 FY26)

Financial Results - Standalone (H1 FY27)

  • Revenue from operations: ₹11,938.11 million (H1 FY27) vs ₹10,097.07 million (H1 FY26)
  • Total income: ₹12,011.90 million (H1 FY27) vs ₹10,346.46 million (H1 FY26)
  • Profit before tax: ₹2,236.42 million (H1 FY27) vs ₹1,888.53 million (H1 FY26)
  • Net profit: ₹1,673.52 million (H1 FY27) vs ₹1,413.19 million (H1 FY26)
  • EPS (Basic): ₹7.89 (H1 FY27) vs ₹6.77 (H1 FY26)
  • EPS (Diluted): ₹7.80 (H1 FY27) vs ₹6.64 (H1 FY26)

Financial Results - Consolidated (Q2 FY27)

  • Revenue from operations: ₹6,585.85 million (Q2 FY27) vs ₹5,374.70 million (Q2 FY26)
  • Profit before tax: ₹1,312.80 million (Q2 FY27) vs ₹1,120.51 million (Q2 FY26)
  • Net profit: ₹983.17 million (Q2 FY27) vs ₹838.44 million (Q2 FY26)
  • EPS (Basic): ₹4.63 (Q2 FY27) vs ₹4.01 (Q2 FY26)
  • EPS (Diluted): ₹4.58 (Q2 FY27) vs ₹3.93 (Q2 FY26)

Financial Results - Consolidated (H1 FY27)

  • Revenue from operations: ₹12,128.70 million (H1 FY27) vs ₹10,338.89 million (H1 FY26)
  • Profit before tax: ₹2,292.54 million (H1 FY27) vs ₹1,927.99 million (H1 FY26)
  • Net profit: ₹1,716.02 million (H1 FY27) vs ₹1,442.99 million (H1 FY26)
  • EPS (Basic): ₹8.09 (H1 FY27) vs ₹6.91 (H1 FY26)
  • EPS (Diluted): ₹8.00 (H1 FY27) vs ₹6.78 (H1 FY26)

Management Appointments

The Board approved the appointment of three Senior Management Personnel effective 05 November 2026:

1. Mr. Sidhartha Das as Senior Vice President & Head Human Resources

  • Seasoned HR professional with 25+ years experience across FMCG, Pharmaceuticals, Life Sciences, and Infrastructure sectors
  • Holds Master's in Social Work and Executive MBA from XLRI
  • Previously associated with the company for two years

2. Mr. Vijay Kumar Suthari as Vice President Head Quality & Regulatory Affairs

  • Pharmaceutical industry professional with 24+ years experience in Quality Assurance, Quality Control, Regulatory Compliance
  • Previously associated with Dr. Reddy's Laboratories Limited, Novartis India Limited, AMRI, and Pfizer India Limited
  • Holds Bachelor of Pharmacy degree from Osmania University

3. Mr. Sriram Gopalakrishnan as Senior Vice President Corporate Communications

  • Marketing and communications professional with 25+ years experience
  • Associated with the company since November 2018
  • Previously held roles at Dr. Reddy's Laboratories and Indian School of Business (ISB)
  • Holds Bachelor's degree in Commerce from University of Delhi and PGP from ISB Hyderabad

ESOP Allotment

The company allotted 108,005 fully paid-up equity shares (face value ₹1 each) upon exercise of options:

  • 27,005 shares under Employees Stock Option Plan 2008 (ESOP 2008) at exercise price ₹188.90 per share
  • 81,000 shares under Management Employee Stock Option Plan 2018 (MESOP 2018) at exercise price ₹23.30 per share

Capital Structure Impact:

  • Pre-allotment paid-up equity capital: ₹21,24,72,716
  • Post-allotment paid-up equity capital: ₹21,25,80,721
  • Increase of ₹108,005 in paid-up capital
  • Distinctive numbers: 21,24,72,717 to 21,25,80,721 (both inclusive)

Balance Sheet Highlights (Standalone as of 30 September 2026)

  • Total assets: ₹41,805.46 million (vs ₹36,028.16 million as of 31 March 2026)
  • Property, plant and equipment: ₹16,886.94 million
  • Capital work-in-progress: ₹5,595.39 million
  • Inventories: ₹2,419.27 million
  • Trade receivables: ₹3,373.11 million
  • Cash and cash equivalents: ₹227.78 million
  • Total equity: ₹27,070.61 million
  • Borrowings (current): ₹4,179.36 million
  • Borrowings (non-current): ₹303.06 million

Cash Flow Highlights (Standalone H1 FY27)

  • Net cash from operating activities: ₹1,772.68 million
  • Net cash used in investing activities: ₹(5,530.75) million (primarily capex of ₹5,612.14 million)
  • Net cash from financing activities: ₹3,199.81 million (primarily from borrowings)
  • Net decrease in cash: ₹(558.26) million

Exceptional Items

An exceptional item of ₹80.01 million was recognized in FY26 related to increased gratuity liability and compensated absences due to implementation of Labour Codes notified on 21 November 2025.

Segment Information

The company operates in a single segment of "Contract Research, Development and Manufacturing Services (CRDMO)".

Subsidiaries Included in Consolidation

1. Sai Life Sciences Inc, USA

2. Sai Life Sciences GmBH, Germany

3. Sai Life Pharma Private Limited, India